-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Zentek Engages Vimta Labs for Clinical Research
Zentek Engages Vimta Labs for Clinical Research
GUELPH, ON / ACCESSWIRE / March 10, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian IP (Intellectual Property) development and commercialization company focused on next-gen healthcare solutions, today announces that it has retained Vimta Labs Limited ("Vimta"), a leading clinical research organization in India, to begin studies of ZEN's ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.
Vimta will be performing pre-clinical research on ZEN's novel graphene oxide-silver active ingredient including collecting the in vitro and in vivo data that is required for the submission of an Investigational New Drug to the United States Food and Drug Administration (FDA) which is a requirement for the administration of a new drug in humans.
The pre-clinical program includes the following research:
- The permeation of the graphene oxide-silver active ingredient in three different formulations to select a formulation that will be used for the remaining studies;
- Analytical and bioanalytical studies to calibrate the detection of the active ingredient in biological samples;
- Acute studies of high dosages of the active ingredient for dermal application;
- Genetic toxicity studies; and
- Safety pharmacology studies and general toxicity studies.
The pre-clinical work with Vimta will begin immediately and is scheduled to be completed by Q4 2022.
The Company decided to move forward with this work following cytotoxicity studies with Nucro-Technics and positive anecdotal results of various human skin infections including acne, warts and toenail fungal infections. There were no adverse effects recorded during these anecdotal trials.
These human anecdotal cases form part of ZEN's patent application filed December 21, 2021, under the Patent Cooperation Treaty entitled "Graphene-Silver Nanocomposites and Uses For Same As a Broad-Spectrum Antimicrobial" which is scheduled to be published on June 22, 2022.
Dr. Kenneth Reed, Dermatologist commented: "Although anecdotal observations are encouraging, the rigorous scientific analysis performed by Vimta will ensure the safety, formulation, and fortify the basic required data needed for FDA review, prior to the potential launch of a new therapeutic agent. The broad-spectrum antimicrobial effects of ZenGUARD™ make it particularly attractive as a topical formulation for the treatment of cutaneous disease with an infectious etiology."
"This is another excellent example of the application opportunities for our broad-spectrum, patent-pending ZenGUARD™ technology," said Dr. Francis Dubé, Executive Chair at Zentek Ltd. "Consistent with our mission to develop innovative nanotechnologies with our partners, Vimta's commitment to high-quality standards and building sustainable relationships will help Zentek to continue creating solutions that improve people's lives."
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Zentek Ltd.
View source version on accesswire.com:
GUELPH, ON / ACCESSWIRE / March 10, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian IP (Intellectual Property) development and commercialization company focused on next-gen healthcare solutions, today announces that it has retained Vimta Labs Limited ("Vimta"), a leading clinical research organization in India, to begin studies of ZEN's ZenGUARD™ active ingredient as a potential treatment of infectious skin disease.
Guelph,on/ACCESSWIRE/2022年3月10日/Zentek Ltd. ("禅宗“或”公司)(多伦多证券交易所股票代码:ZEN和OTC PINK:ZENYF),一家专注于下一代医疗解决方案的加拿大知识产权(知识产权)开发和商业化公司,今天宣布,它已经聘请了印度领先的临床研究机构Vimta Labs Limited(简称Vimta),开始对Zen的Zen进行研究警卫™活性成分作为治疗感染性皮肤病的潜在药物。
Vimta will be performing pre-clinical research on ZEN's novel graphene oxide-silver active ingredient including collecting the in vitro and in vivo data that is required for the submission of an Investigational New Drug to the United States Food and Drug Administration (FDA) which is a requirement for the administration of a new drug in humans.
Vimta将对Zen的新型氧化石墨烯-银活性成分进行临床前研究,包括收集体外和体内向美国食品和药物管理局(FDA)提交研究用新药所需的数据,这是在人体内使用新药的要求。
The pre-clinical program includes the following research:
临床前计划包括以下研究:
- The permeation of the graphene oxide-silver active ingredient in three different formulations to select a formulation that will be used for the remaining studies;
- Analytical and bioanalytical studies to calibrate the detection of the active ingredient in biological samples;
- Acute studies of high dosages of the active ingredient for dermal application;
- Genetic toxicity studies; and
- Safety pharmacology studies and general toxicity studies.
- 石墨烯氧化物-银活性成分在三种不同配方中的渗透,以选择将用于剩余研究的配方;
- 进行分析和生物分析研究,以校准生物样品中活性成分的检测;
- 皮肤应用的高剂量活性成分的急性研究;
- 遗传毒性研究;以及
- 安全性药理研究和一般毒性研究。
The pre-clinical work with Vimta will begin immediately and is scheduled to be completed by Q4 2022.
Vimta的临床前工作将立即开始,计划于2022年第四季度完成。
The Company decided to move forward with this work following cytotoxicity studies with Nucro-Technics and positive anecdotal results of various human skin infections including acne, warts and toenail fungal infections. There were no adverse effects recorded during these anecdotal trials.
该公司在利用Nucro-Technics进行了细胞毒性研究,并在包括粉刺、疣和趾甲真菌感染在内的各种人类皮肤感染的轶事结果呈阳性后,决定推进这项工作。在这些轶事试验中,没有记录到不良反应。
These human anecdotal cases form part of ZEN's patent application filed December 21, 2021, under the Patent Cooperation Treaty entitled "Graphene-Silver Nanocomposites and Uses For Same As a Broad-Spectrum Antimicrobial" which is scheduled to be published on June 22, 2022.
这些人类轶事案例是Zen根据专利合作条约提交的2021年12月21日提交的专利申请的一部分,该条约题为《石墨烯-银纳米复合材料及其作为广谱抗菌剂的用途》,该条约计划于2022年6月22日公布。
Dr. Kenneth Reed, Dermatologist commented: "Although anecdotal observations are encouraging, the rigorous scientific analysis performed by Vimta will ensure the safety, formulation, and fortify the basic required data needed for FDA review, prior to the potential launch of a new therapeutic agent. The broad-spectrum antimicrobial effects of ZenGUARD™ make it particularly attractive as a topical formulation for the treatment of cutaneous disease with an infectious etiology."
皮肤科医生Kenneth Reed评论说:“虽然轶事观察令人鼓舞,但Vimta进行的严格科学分析将确保安全性、配方和加强FDA审查所需的基本数据,在可能推出新的治疗剂之前。Zen的广谱抗菌作用警卫™使其作为治疗感染性皮肤病的外用制剂特别有吸引力。“
"This is another excellent example of the application opportunities for our broad-spectrum, patent-pending ZenGUARD™ technology," said Dr. Francis Dubé, Executive Chair at Zentek Ltd. "Consistent with our mission to develop innovative nanotechnologies with our partners, Vimta's commitment to high-quality standards and building sustainable relationships will help Zentek to continue creating solutions that improve people's lives."
这是我们正在申请专利的广谱禅宗应用机会的又一个极好的例子。警卫™公司执行主席Francis Dubé博士说,“与我们与合作伙伴共同开发创新纳米技术的使命一致,Vimta对高质量标准和建立可持续关系的承诺将帮助Zentek继续创造改善人们生活的解决方案。”
About Zentek Ltd.
关于Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
Zentek是一家知识产权开发和商业化公司,专注于预防、检测和治疗领域的下一代医疗解决方案。Zentek目前专注于将禅宗商业化警卫™,一种正在申请专利的涂料,被证明具有99%的抗菌活性,包括对新冠肺炎的抗菌活性,并有可能将类似化合物用作治疗传染病的产品。该公司还达成了一项独家协议,将成为一种新开发的基于适体的快速病原体检测技术的全球独家商业化合作伙伴。
For further information:
有关更多信息,请访问:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
马特·布拉泽
电话:(212)655-0924
电子邮件:mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at
欲了解更多有关Zentek Ltd.的信息,请访问我们的网站:。本新闻稿和与公司有关的所有重要文件的副本可在Zen的SEDAR简介中获得,网址为
Forward-Looking Statements
前瞻性陈述
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
本新闻稿包含前瞻性陈述。由于前瞻性陈述涉及未来的事件和情况,它们本身就具有内在的风险和不确定性。尽管Zentek认为,在准备本新闻稿中的前瞻性信息时使用的假设和因素是合理的,但不应过度依赖这些信息,因为这些信息仅适用于本新闻稿发布之日,并且不能保证此类事件将在披露的时间框架内发生或根本不会发生。除法律要求外,Zentek没有任何更新或修改任何前瞻性信息的意图或义务,无论是由于新信息、未来事件还是其他原因。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所创业板交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
SOURCE: Zentek Ltd.
资料来源:Zentek Ltd.
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧